Skip to content
Buy This GLP
← Research
Evidence

GLP-1 and SGLT2 Use From 2017 to 2023: Who Was Left Out as Use Rose Tenfold

Use of GLP-1 drugs and SGLT2 inhibitors rose from 0.42% to 4.45% of adults between 2017 and 2023, while per-prescription spending rose nearly 50%. Uninsured adults had 0.53 times the odds of use.

Editorial profile: Carla MedinaBuy This GLP Editorial Team7 min read
Adjusted odds of use by groupparity (1.0)uninsured0.53low education0.67low income0.73Hispanic adults0.74Black adults0.78

The GLP-1 monthly cost guide describes the prices patients may encounter. A separate analysis of seven years of the Medical Expenditure Panel Survey looked at who received treatment as use grew [1]. Overall use rose from 0.42% to 4.45% of adults. Among adults with a condition for which the drugs are approved, it rose from 8.50% to 31.36%.

For someone who has insurance and receives a denial, the Wegovy appeal guide explains where to find the plan’s reason and how to respond. Spending per prescription rose by nearly half over the same period. The survey analysis measured use and spending. It cannot establish whether rising prices caused the differences in use across groups.

Compared with privately insured adults, uninsured adults had lower adjusted odds of using either drug class (OR 0.53, 95% CI 0.31–0.92). The study also reported lower odds for middle- and lower-income adults compared with higher-income adults, and for Black and Hispanic adults compared with White adults. These estimates use a separate reference category for each characteristic.

One measurement caveat carries through everything above. The study reports GLP-1 drugs and SGLT2 inhibitors as a single utilization outcome, so none of these odds ratios is a GLP-1 figure on its own, and the two classes have different prices, different indications and different coverage rules. The direction is clear and the attribution to one class is not available.

The GLP-1 insurance coverage guide explains how coverage rules can affect out-of-pocket costs. If you get insurance through work, the employer coverage guide explains what to ask your benefits team. The study above combines two drug classes and does not estimate access through any specific employer plan.

Frequently asked

How did use differ by insurance status?
Uninsured adults had 0.53 times the adjusted odds of using either drug class compared with privately insured adults. Lower odds also appeared for adults with less education, for middle- and low-income earners, and for Black and Hispanic adults.
Are these drugs mostly used off-label?
Not according to this data. Off-label use fell from 27% to 12% between 2017 and 2023, while overall use rose about tenfold.
Do these figures describe GLP-1 drugs specifically?
No. The study combines GLP-1 receptor agonists and SGLT2 inhibitors into one utilization measure, so the disparities cannot be attributed to either class on its own.

Sources

  1. [1] Jacobs M, Fang Q, Ellis C (2026). Trends in GLP-1 Receptor Agonist and SGLT2-Inhibitor Utilization and Expenditure Between 2017-2023: Demographic, Income, and Insurance Associations Journal of General Internal Medicine. PMID 41984414

Where to get it

The cheapest GLP-1

Every seller that publishes a price, ordered lowest first on the standing month-to-month rate, plus the question to ask before you pay any of them.

See the board →

More in Evidence